WASHINGTON — The U.S. Food and Drug Administration is not planning to seek advice from its outside advisers over Dendreon Corp.'s experimental prostate cancer vaccine, Reuters reported March 5.
WASHINGTON — The U.S. Food and Drug Administration is not planning to seek advice from its outside advisers over Dendreon Corp.'s experimental prostate cancer vaccine, Reuters reported March 5.
An investigational vaccine for the asbestos-related cancer mesothelioma is safe, according to a new study cited in a press release March 4 from the American Thoracic Society.
BUFFALO, N.Y. — A University at Buffalo cancer researcher has received a $300,000 grant from King Saud University to continue her work with a Saudi researcher on a vaccine for breast cancer, the schools announced Jan. 21.
TAMPA, Fla. — Biovest International Inc. announced Jan. 7 that the U.S. Food and Drug Administration has granted orphan drug designation to BiovaxID, Biovest’s personalized lymphoma vaccine.
GOTHENBURG, Sweden — New research at Sahlgrenska Academy might be an important step toward creating a vaccine against ulcers and stomach cancer, The Local reported Dec. 30.
HALIFAX, NOVA SCOTIA — Immunovaccine Inc. announced Dec. 9 that its Investigational New Drug (IND) application for its therapeutic cancer vaccine, DPX-0907, has been cleared by the U.S. Food and Drug Administration.
SEATTLE — Oncothyreon Inc. announced Dec. 10 that its development partner Merck KGaA started a late-stage trial of its cancer vaccine in patients in Asia with advanced non-small cell lung cancer.
MENLO PARK, Calif. — Geron Corp. announced Dec. 8 the presentation of interim data from its phase II trial of GRNVAC1, an autologous dendritic cell vaccine, in patients with acute myelogenous leukemia at the 51st Annual Meeting of the American Society of
CALCUTTA, India — Cervical cancer vaccines should cost less to be more effective in lowering the death rate caused by the disease a Nobel laureate said, according to a report in The Times of India on Dec. 3.
HALIFAX, Nova Scotia — Immunovaccine Inc. announced Nov. 2 that it entered into an agreement with Cato Research Canada Inc. to assist it in managing an upcoming Phase 1 clinical trial for DPX-0907.